The efficacy of erlotinib as molecularly targeted maintenance therapy in advanced non-small-cell lung cancer (NSCLC): Case reports in western Iran

Abstract

In developing countries, majority of cancer patients have low income. Therefore, we could hardly do maintenance therapy about the number of patients with non-small-cell lung cancer and other cancers. Maintenance therapy for advanced non-small-cell lung cancer (NSCLC) refers to the use of an effective agent in the absence of disease progression following platinum-based combination chemotherapy to improve progression-free survival. In our Clinic, we identified three cancerous patients with metastasis for lung cancer. The Epidermal Growth Factor Receptor mutation on exon 19 started erlotinib therapy for several courses. After a short time, in all patients, lesions decreased and patients became stable.